AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26188932 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel
Number of subjects: 270
Study 26188932 — intervention group
Group type: EXPERIMENTAL
Intervention: eugenol-based paste
Number of subjects: 270
Study 26188932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 270
Study 23294685 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity low-amplitude thrust (HVLAT)
Number of subjects: 10
Study 23294685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham functional technique (SFT)
Number of subjects: 10
Study 23294685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham ultrasound (SUS)
Number of subjects: 10
Study 23294685 — intervention group
Group type: COMPARATOR
Intervention: No intervention control (NIC)
Number of subjects: 10
Study 21978211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Hyalgan®)
Number of subjects: 200
Study 21978211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 17693145 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Carnitine (2 g daily for 180 days)
Number of subjects: 60
Study 17693145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14684587 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa, ribavirin, and amantadine
Number of subjects: 171
Study 14684587 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa and ribavirin
Number of subjects: 171
Study 12134281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (2.25 mg/day)
Number of subjects: 1
Study 12134281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 9813510 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine
Number of subjects: 40
Study 9813510 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40
Study 7656739 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive drainage (PD)
Number of subjects: 186
Study 7656739 — intervention group
Group type: COMPARATOR
Intervention: Closed suction drainage (SD)
Number of subjects: 186
Study 2682242 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure (117 +/- 4.4 ppm)
Number of subjects: 63
Study 2682242 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure (253 +/- 6.1 ppm)
Number of subjects: 63
Study 2682242 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 63
Study 15762 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg thrice daily with meals)
Number of subjects: 9
Study 15762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prindolol (5 mg thrice daily with meals)
Number of subjects: 9
Study 15762 — intervention group
Group type: COMPARATOR
Intervention: Methyclothiazide (5 mg with breakfast)
Number of subjects: 9
Study 15762 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol doses (120 mg, 60 mg, 40 mg with meals)
Number of subjects: 9
Study 15762 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg with breakfast, 100 mg with breakfast and evening meal)
Number of subjects: 9
Study 15762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prindolol (30 mg, 15 mg, 10 mg with meals)
Number of subjects: 9
Study 31368283 — intervention group
Group type: EXPERIMENTAL
Intervention: Blade needle therapy (longitudinal cutting along the musculoaponeurotic layer) applied to tender points of the head and neck, treatment conducted once every 3 days for 15 days.
Number of subjects: 60
Study 31368283 — intervention group
Group type: COMPARATOR
Intervention: Medication group receiving Flunarizine Hydrochloride capsules (10 mg) once every night for 15 days.
Number of subjects: 60
Study 27804900 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTATE (n = 53)
Number of subjects: 86
Study 27804900 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WLC) (n = 33)
Number of subjects: 86
Study 25944513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnia trial (voluntary hyperventilation, minute ventilation = 31 L min(‐1))
Number of subjects: 9
Study 25944513 — intervention group
Group type: COMPARATOR
Intervention: Control trial (spontaneous breathing, minute ventilation = 14 L min(‐1))
Number of subjects: 9
Study 25944513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnia trial
Number of subjects: 9
Study 25944513 — intervention group
Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 9
Study 22854773 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory return-to-work (RTW) program
Number of subjects: 163
Study 22854773 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 163
Study 21971743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting up for five minutes after spinal anesthesia (Group S)
Number of subjects: 120
Study 21971743 — intervention group
Group type: COMPARATOR
Intervention: Lying down immediately after spinal anesthesia (Group L)
Number of subjects: 120
Study 19463339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracellular calcium modulator as adjunct to primary PCI
Number of subjects: 378
Study 16491425 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-DOTA-TOC
Number of subjects: 45
Study 16491425 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-DOTA-LAN
Number of subjects: 45
Study 15120774 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 250
Study 15120774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 250
Study 15120774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 11275926 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 6519
Study 11275926 — intervention group
Group type: COMPARATOR
Intervention: smoking status
Number of subjects: 6519
Study 9831269 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 8
Study 9831269 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 8
Study 7862803 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (885)
Number of subjects: 6900
Study 7862803 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers (6,015)
Number of subjects: 6900
Study 2571021 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (50 mg/kg, orally in a syrup preparation)
Number of subjects: 23
Study 2571021 — intervention group
Group type: COMPARATOR
Intervention: Control syrup (no active treatment)
Number of subjects: 23
Study 1277749 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin infusion at 12.5 units/min for 1 h
Number of subjects: 7
Study 1277749 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin infusion at 25 units/min for 1 h
Number of subjects: 7
Study 1277749 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin infusion (both doses)
Number of subjects: 7
Study 31987677 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical simulator training (30 hours)
Number of subjects: 12
Study 31987677 — intervention group
Group type: COMPARATOR
Intervention: No simulator training
Number of subjects: 12
Study 31423869 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target of <130 mm Hg
Number of subjects: 3020
Study 31423869 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure target of 130 to 149 mm Hg
Number of subjects: 3020
Study 27978602 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Implant (IMI)
Number of subjects: 124
Study 27978602 — intervention group
Group type: COMPARATOR
Intervention: Delayed Implant (DI)
Number of subjects: 124
Study 27978602 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient reported outcomes
Number of subjects: 124
Study 26231756 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rehabilitation intervention (low-intensity exercise programme consisting of aerobic, coordination and visualisation exercises)
Number of subjects: 0
Study 26231756 — intervention group
Group type: COMPARATOR
Intervention: Standard care education group
Number of subjects: 0
Study 23591282 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injections (8 × 12.5 U)
Number of subjects: 22
Study 23591282 — intervention group
Group type: COMPARATOR
Intervention: Saline injections (8 × 0.5 mL)
Number of subjects: 22
Study 20926105 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive repair via right minithoracotomy (MI group)
Number of subjects: 70
Study 20926105 — intervention group
Group type: COMPARATOR
Intervention: Conventional open repair via median sternotomy (MS group)
Number of subjects: 70
Study 20926105 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MI and MS)
Number of subjects: 70
Study 19901006 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sexual and alcohol risk reduction (GPI + GMET)
Number of subjects: 484
Study 19901006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk reduction only (GPI)
Number of subjects: 484
Study 19901006 — intervention group
Group type: COMPARATOR
Intervention: HIV/sexually transmitted disease prevention information only (GINFO)
Number of subjects: 484
Study 19901006 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI + GMET
Number of subjects: 484
Study 16450086 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (A) regimen: A 125 mg p.o. plus ondansetron (O) 32 mg and dexamethasone (D) 12 mg on day 1; A 80 mg and D 8 mg once daily on days 2-3; and D 8 mg on day 4.
Number of subjects: 1044
Study 16450086 — intervention group
Group type: COMPARATOR
Intervention: Control regimen: Ondansetron (O) 32 mg i.v. and dexamethasone (D) 20 mg p.o. on day 1; D 8 mg twice daily on days 2-4.
Number of subjects: 1044
Study 16450086 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (A) regimen
Number of subjects: 1044
Study 16450086 — intervention group
Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 1044
Study 15223402 — intervention group
Group type: EXPERIMENTAL
Intervention: No retransfusion of cardiotomy suction blood and mediastinal shed blood
Number of subjects: 29
Study 15223402 — intervention group
Group type: COMPARATOR
Intervention: Retransfusion of cardiotomy suction blood and mediastinal shed blood
Number of subjects: 29
Study 11723278 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta1b (8 x 10(6) IU)
Number of subjects: 718
Study 11723278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study 9140160 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose UDCA (10 mg/kg/day)
Number of subjects: 30
Study 9140160 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UDCA (20 mg/kg/day)
Number of subjects: 30
Study 7963019 — intervention group
Group type: EXPERIMENTAL
Intervention: GELP synthesizer with glottal excitation codebook (32 entries) and stochastic codebook (256 entries) for unvoiced noise excitation.
Number of subjects: 0
Study 7963019 — intervention group
Group type: EXPERIMENTAL
Intervention: GELP synthesizer
Number of subjects: 0
Study 3300423 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid lidocaine 1 mg/kg plus salmon calcitonin (sCT) 100 IU
Number of subjects: 60
Study 3300423 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid lidocaine plus saline
Number of subjects: 60
Study 31536766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% Î²G supplementation
Number of subjects: 270
Study 31536766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/20 FP + 0.4% Î²G
Number of subjects: 270
Study 31536766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/10 FP + 0.4% Î²G
Number of subjects: 270
Study 31536766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% Î²G
Number of subjects: 270
Study 31536766 — intervention group
Group type: COMPARATOR
Intervention: FP exposure
Number of subjects: 270
Study 28540394 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-year oral health programme
Number of subjects: 90
Study 28540394 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 26856306 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple postal intervention highlighting the importance of maintaining asthma medication
Number of subjects: 0
Study 24499161 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Active Living (HAL) community intervention
Number of subjects: 60
Study 24499161 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control residence
Number of subjects: 60
Study 22152079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO(2) = 0.4)
Number of subjects: 20
Study 22152079 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 20
Study 19618788 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum relapse prevention interventions that address SHS exposure
Number of subjects: 11
Study 19618788 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention prioritizing parental education on SHS effects, empowerment to remain abstinent, and adoption of smoke-free home policy
Number of subjects: 11
Study 17495782 — intervention group
Group type: EXPERIMENTAL
Intervention: Curare (cholinergic blockade)
Number of subjects: 20
Study 17495782 — intervention group
Group type: COMPARATOR
Intervention: No curare (control group)
Number of subjects: 20
Study 15708844 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/day hypericum extract WS 5570 three times a day for six weeks
Number of subjects: 251
Study 15708844 — intervention group
Group type: COMPARATOR
Intervention: 20 mg paroxetine once a day for six weeks
Number of subjects: 251
Study 15708844 — intervention group
Group type: EXPERIMENTAL
Intervention: hypericum extract WS 5570
Number of subjects: 251
Study 15708844 — intervention group
Group type: COMPARATOR
Intervention: paroxetine
Number of subjects: 251
Study 12408204 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard behavioral treatment group including a couples intervention
Number of subjects: 160
Study 12408204 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral treatment group
Number of subjects: 160
Study 9583482 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAM flap
Number of subjects: 0
Study 9583482 — intervention group
Group type: EXPERIMENTAL
Intervention: Latissimus dorsi flap
Number of subjects: 0
Study 9583482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral thoracodorsal flap
Number of subjects: 0
Study 9583482 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study 7657029 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp (plasma insulin concentration 586 +/- 9.7 pmol/l) for 13 hours
Number of subjects: 7
Study 7657029 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion for 13 hours (control)
Number of subjects: 7
Study 7657029 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp
Number of subjects: 7
Study 2652546 — intervention group
Group type: EXPERIMENTAL
Intervention: Aza and Pred (Group I)
Number of subjects: 48
Study 2652546 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA alone (Group II)
Number of subjects: 48
Study 2652546 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA and steroids (Group III)
Number of subjects: 48
Study 2652546 — intervention group
Group type: COMPARATOR
Intervention: Aza (previous study)
Number of subjects: 48
Study 791585 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (150 mg/day) plus placebo
Number of subjects: 32
Study 791585 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day) plus proglumide (900 mg/day)
Number of subjects: 32
Study 31180155 — intervention group
Group type: COMPARATOR
Intervention: Control CL (single vision, silicone hydrogel contact lenses)
Number of subjects: 508
Study 31180155 — intervention group
Group type: EXPERIMENTAL
Intervention: Test CL I (myopic defocus +1.00D centrally and +2.50D at 3 mm semi-chord)
Number of subjects: 508
Study 31180155 — intervention group
Group type: EXPERIMENTAL
Intervention: Test CL II (myopic defocus +1.00D centrally and +1.50D at 3 mm semi-chord)
Number of subjects: 508
Study 31180155 — intervention group
Group type: EXPERIMENTAL
Intervention: Test CL III (EDOF hydrogel CL with extended depth of focus +1.75D)
Number of subjects: 508
Study 31180155 — intervention group
Group type: EXPERIMENTAL
Intervention: Test CL IV (EDOF hydrogel CL with extended depth of focus +2.50D)
Number of subjects: 508
Study 31180155 — intervention group
Group type: EXPERIMENTAL
Intervention: Test CL (compliant wearers ≥6 days per week)
Number of subjects: 508
Study 28677982 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride (TG) alone
Number of subjects: 1994
Study 28677982 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride (TG) in combination with waist circumference (WC)
Number of subjects: 1994
Study 28677982 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight in women
Number of subjects: 1994
Study 28677982 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity in women
Number of subjects: 1994
Study 28677982 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight in men
Number of subjects: 1994
Study 28677982 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity in men
Number of subjects: 1994
Study 28677982 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy diet in women
Number of subjects: 1994
Study 28677982 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Cola consumption in women
Number of subjects: 1994
Study 28677982 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance in women
Number of subjects: 1994
Study 25461685 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 30
Study 25461685 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 30
Study 25461685 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference
Number of subjects: 30
Study 24617605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (1 mg) with rifampicin (600 mg)
Number of subjects: 16
Study 24617605 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 mg) with rifampicin (600 mg)
Number of subjects: 16
Study 22733794 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed computer treatment with volunteer support
Number of subjects: 34
Study 22733794 — intervention group
Group type: COMPARATOR
Intervention: Usual care (everyday language activity)
Number of subjects: 34
Study 19540443 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% formalin (group A)
Number of subjects: 66
Study 19540443 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% sodium azide (group B)
Number of subjects: 66
Study 19540443 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (group C)
Number of subjects: 66
Study 17470740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily)
Number of subjects: 5408
Study 17470740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5408
Study 15697102 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (NuvaRing) delivering 15 microg ethinylestradiol and 120 microg etonogestrel per day
Number of subjects: 0
Study 15697102 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel
Number of subjects: 0
Study 16158750 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (15 mg/day, titrated to a maximum of 45 mg)
Number of subjects: 66
Study 16158750 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride (30 mg and then 45 mg/day for 3 patients)
Number of subjects: 66
Study 10227614 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 80
Study 10227614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9074901 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate plus magnesium carbonate (Rennie)
Number of subjects: 12
Study 9074901 — intervention group
Group type: COMPARATOR
Intervention: Hydrotalcite (Talcid)
Number of subjects: 12
Study 1653137 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 1130
Study 1653137 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sumatriptan
Number of subjects: 1130
Study 1653137 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg sumatriptan
Number of subjects: 1130
Study 1653137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1130
Study 1653137 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatment groups (100 mg, 200 mg, 300 mg sumatriptan)
Number of subjects: 1130
Study 1653137 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (all doses)
Number of subjects: 1130
Study 6684027 — intervention group
Group type: EXPERIMENTAL
Intervention: NH4Cl (ammonium chloride) group
Number of subjects: 11
Study 6684027 — intervention group
Group type: COMPARATOR
Intervention: CaCO3 (calcium carbonate) placebo control group
Number of subjects: 11
Study 30552060 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 0
Study 30552060 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine
Number of subjects: 0
Study 30552060 — intervention group
Group type: COMPARATOR
Intervention: Combined administration of tyrosine with cathodal tDCS
Number of subjects: 0
Study 29788418 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 1554
Study 29788418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1554
Study 27501604 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided technique (US-group)
Number of subjects: 100
Study 27501604 — intervention group
Group type: COMPARATOR
Intervention: Palpation technique (P-group)
Number of subjects: 100
Study 24218517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 572
Study 24218517 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 572
Study 22634075 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital clinic group-based intervention
Number of subjects: 110
Study 22634075 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention
Number of subjects: 110
Study 22634075 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 20547639 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI of the brain
Number of subjects: 953